(Q46741009)

English

How long can patients with mild or moderate Alzheimer's dementia maintain both the cognition and the therapy of cholinesterase inhibitors: a national population-based study

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18290848

How long can patients with mild or moderate Alzheimer's dementia maintain both the cognition and the therapy of cholinesterase inhibitors: a national population-based study (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18290848

0 references

0 references

2

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18290848

author name string

Y Sun

1

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18290848

C-J Lu

3

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18290848

R-C Chen

4

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18290848

publication date

1 March 2008

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18290848

European Journal of Neurology

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18290848

15

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18290848

3

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18290848

278-283

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18290848

Determinants of costs of care for patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.02049.X

21 January 2018

Economic aspects on drug therapy of dementia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.02049.X

21 January 2018

Pharmacoeconomics of cholinesterase inhibitors in the treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.02049.X

21 January 2018

Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.02049.X

21 January 2018

Cost effectiveness of cholinesterase inhibitors in the treatment of Alzheimer's disease: a review with methodological considerations

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.02049.X

21 January 2018

Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.02049.X

21 January 2018

Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.02049.X

21 January 2018

Global prevalence of dementia: a Delphi consensus study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.02049.X

21 January 2018

Prevalence and subtypes of dementia in Taiwan: a community survey of 5297 individuals

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.02049.X

21 January 2018

Alzheimer's disease under managed care: implications from Medicare utilization and expenditure patterns

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.02049.X

21 January 2018

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.02049.X

21 January 2018

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.02049.X

21 January 2018

A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.02049.X

21 January 2018

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.02049.X

21 January 2018

Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.02049.X

21 January 2018

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.02049.X

21 January 2018

Natural history of Alzheimer's disease and other dementias: review of the literature in the light of the findings from the Kungsholmen Project.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.02049.X

21 January 2018

A controlled study of survival with dementia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.02049.X

21 January 2018

The prevalence of dementia in a total population: a comparison of two screening instruments.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.02049.X

21 January 2018

Long-term cognitive and functional decline in late onset Alzheimer's disease: therapeutic implications.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.02049.X

21 January 2018

Donepezil. Pharmacoeconomic implications of therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.02049.X

21 January 2018

Adherence to Medication

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.02049.X

21 January 2018

Assessment of health economics in Alzheimer's disease (AHEAD) based on need for full-time care.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.02049.X

21 January 2018

Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.02049.X

21 January 2018

Assessment of Health Economics in Alzheimer's Disease (AHEAD): treatment with galantamine in Sweden

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.02049.X

21 January 2018

Assessment of health economics in Alzheimer's disease (AHEAD): galantamine treatment in Canada

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.02049.X

21 January 2018

The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: a Markov model.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.02049.X

21 January 2018

Savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmine.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.02049.X

21 January 2018

Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.02049.X

21 January 2018

Identifiers

10.1111/J.1468-1331.2007.02049.X

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18290848

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18290848

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46741009&oldid=2129516579"